as 05-17-2024 4:00pm EST
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 252.0M | IPO Year: | 2020 |
Target Price: | $8.00 | AVG Volume (30 days): | 245.0K |
Analyst Decision: | Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.55 | EPS Growth: | N/A |
52 Week Low/High: | $0.86 - $6.98 | Next Earning Date: | 05-13-2024 |
Revenue: | $9,963,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | 35.45% | Revenue Growth (next year): | -15.01% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Appelhans Dannielle | GBIO | Director | Dec 8 '23 | Buy | $1.82 | 637 | $1,159.34 | 12,637 | SEC Form 4 |
Appelhans Dannielle | GBIO | Director | Dec 8 '23 | Buy | $1.79 | 7,363 | $13,179.77 | 7,363 | SEC Form 4 |
Appelhans Dannielle | GBIO | Director | Dec 4 '23 | Buy | $1.50 | 12,000 | $18,000.00 | 12,000 | SEC Form 4 |
Quinn Anthony G. | GBIO | Director | Dec 1 '23 | Buy | $1.41 | 88,495 | $124,777.95 | 88,495 | SEC Form 4 |
Rowland Charles A Jr | GBIO | Director | Dec 1 '23 | Buy | $1.31 | 192,960 | $252,777.60 | 384,757 | SEC Form 4 |
Rowland Charles A Jr | GBIO | Director | Dec 1 '23 | Buy | $1.50 | 150,000 | $225,000.00 | 534,757 | SEC Form 4 |
Nicholson Donald William | GBIO | Director | Dec 1 '23 | Buy | $1.44 | 100,000 | $144,000.00 | 213,576 | SEC Form 4 |
GBIO Breaking Stock News: Dive into GBIO Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
GlobeNewswire
6 days ago
GlobeNewswire
11 days ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
GuruFocus.com
2 months ago
Zacks
2 months ago
GlobeNewswire
2 months ago